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Confocal analysisThe nitric oxide (NO) prodrug JS-K is shown to have anticancer activity. To proﬁle the molecular events
associated with the anticancer effects of JS-K, HL-60 leukemia cells were treated with JS-K and subjected to
microarray and real-time RT-PCR analysis. JS-K induced concentration- and time-dependent gene expression
changes in HL-60 cells corresponding to the cytolethality effects. The apoptotic genes (caspases, Bax, and
TNF-α) were induced, and differentiation-related genes (CD14, ITGAM, and VIM) were increased. For acute
phase protein genes, some were increased (TP53, JUN) while others were suppressed (c-myc, cyclin E). The
expression of anti-angiogenesis genes THBS1 and CD36 and genes involved in tumor cell migration such as
tissue inhibitors of metalloproteinases, were also increased by JS-K. Confocal analysis conﬁrmed key gene
changes at the protein levels. Thus, multiple molecular events are associated with JS-K effects in killing HL-
60, which could be molecular targets for this novel anticancer NO prodrug.Published by Elsevier Inc.Introduction
Nitric oxide (NO) inhibits the growth and induces differentiation
of acute myeloid leukemia cells [1,2]. Expression of human monocyte
differentiation markers CD11b and CD14, and tumor necrosis factor-α
(TNF-α) and interleukin-1β (IL-1β) transcripts in leukemia cells can
be increased by NO [1.2]. Spontaneous NO generating diazeniumdio-
late compounds induce apoptosis in acute myeloid leukemia HL-60
and U937 cells [3], with the long half-life (20 h) NO donor DETA-NO
being themost active. Themajor obstacle for the use of NO-generating
compounds in vivo to treat malignant disease is NO-induced
vasodilation [4]. An alternative approach is the use of NO-generating
prodrugs that would be activated in the targeted cells, thus avoiding
the vascular effects of the drug. For instance, esterase-activated
diazeniumdiolates that do not release NO spontaneously but rather
are enzymatically activated to release NO are cytotoxic to leukemia
cells [5]. However, such a drug design is unlikely to provide enough
selectivity because esterases are ubiquitous. Many malignant cells,
including leukemia cells, overexpress glutathione S-transferasesami@utah.edu (P.J. Shami).
Inc.(GST) which result in resistance to cytotoxic compounds through
glutathione (GSH) conjugation and cellular efﬂux via multi-drug
resistance (MRP) pumps, or by inhibition of mitogen activated protein
kinases (MAPK) [6]. Consequently, GST constitutes an attractive
enzyme system for the targeting of cytotoxic agents to cancer cells.
O2-arylated diazeniumdiolates are designed to release NO upon
conjugation with GSH in a reaction catalyzed by GST. O2-(2,4-
dinitrophenyl) 1-[(4-ethoxyxarbonyl)piperazin-1-yl]diazen-1-ium-
1,2-diolate (JS-K), the lead compound from this family is potently
cytotoxic to human myeloid leukemia HL-60 cells in vitro and in vivo
[7]. JS-K also inhibits hepatoma Hep 3B cell proliferation [8], enhances
arsenic- and cisplatin-induced cytolethality in arsenic-transformed
rat liver cells [9], and induces apoptosis in human multiple myeloma
cell lines [10]. In the National Cancer Institute 51-cell panel screen, JS-
K was effective against leukemia, renal cancer cells, prostate cancer
cells, and brain cancer cells [11,12]. In in vivomurine models, JS-K was
effective in inhibiting the growth of HL-60 (leukemia) [7], PPC-1
(prostate cancer) [7], JM-1 (hepatoma) [11], and OPM1 cells
(myeloma) [10]. Consequently, JS-K is a lead compound establishing
a new class of cancer chemotherapeutic agents [12].
Mechanisms for the antineoplastic effects of JS-K are not com-
pletely elucidated. In HL-60 cells, JS-K induces differentiation and
apoptosis. JS-K-induced apoptosis in HL-60 cells occurs through
activation of both the intrinsic and extrinsic pathways [7,13]. Apoptosis
33J. Liu et al. / Genomics 94 (2009) 32–38induction by JS-K is mediated, at least in part, by cytochrome c release
and caspase activation [13]. The goal of the present study was to use
microarray and real-time polymerase chain reaction (RT-PCR) analysis
to identify genes that are modulated by JS-K in killing HL-60 cells.
Confocal image analysis was also performed on selected proteins.
Results demonstrate thatmultiplemolecular events are likely involved
in the antitumor effects of JS-K, including activation of caspases,
modulation of cell growth and differentiation genes, increased
expression of anti-angiogenesis genes and genes inhibiting tumor
cell migration, all of which could be potential molecular targets for the
anticancer effects of JS-K.
Materials and methods
Materials
JS-K was synthesized as previously described [14]. The Clontech
Human Cancer Arrays (600 genes) were purchased from Clontech
(Palo Alto, CA). All the primers for RT-PCR analysis were synthesized
by Sigma-Genosys (The Woodlands, TX). All other chemicals were of
reagent grade.
Cell culture and JS-K treatment
Human myeloid leukemia HL-60 cells (ATCC, Manassas, VA) were
cultured in RPMI-1640 supplemented with 10% fetal bovine serum
(FBS) and penicillin/streptomycin. Cells were cultured at 37 °C in a 5%
CO2 humidiﬁed atmosphere. JS-K stock (5 mM) was prepared with
dimethyl sulfoxide (DMSO) and diluted in phosphate buffered saline
(PBS) before addition to cultures. The ﬁnal concentration of DMSO
added to the cultures was less than 0.1% and themedia containing 0.1%
DMSO was used as controls. JS-K was added to HL-60 cells at
concentrations of 0, 0.25, 0.5, and 1.0 μM, and cells were harvested 2, 4,
6, and 24 h later.
RNA isolation
At the end of JS-K treatments, cells were harvested by centrifuga-
tion and total RNA was isolated with TRIzol agent (Invitrogen,
Carlsbad, CA), followed by puriﬁcation and DNase-I digestion with
RNeasy columns (Qiagen, Valencia, CA). The quality of RNA was
determined by the 260/280 ratios, and by gel electrophoresis to
visualize the integrity of 18S and 28S bands.Table 1
Primer sequences for real-time RT-PCR analysis.
Gene GenBank number Forward
β-actin X00351 GTCCACC
BAX NM_004324 CCGCCGT
CASP3 NM_004346 TGGTTCA
CASP8 NM_001228 ACCAGG
JUN J04111 CCAAAG
MYC V00568 GAGGCG
ITGAM M82856 CGCCCTC
CD14 M86511 TAACCTG
CD36 NM_031561 GGCTAA
CCNE1 X75888 GCCCTTA
EGR1 X52541 TGAACG
IL1B NM_000576 CTTAAAG
MMP9 NM_004994 GGACGA
MMP11 X57766 CCGCCTC
TP53 M14694 CCCAGCC
TIMP1 NM003254 TCCCTGC
TIMP2 NM003255 TCACCCT
TIMP3 NM000362 AACTTGG
TNF NM_000594 CCTCAAC
THBS1 X14787 CATGCCA
VIM X56134 CGCCAAMicroarray analysis
Approximately 5 mg of total RNA was converted to [a-32P]-dATP-
labeled cDNA probe using MuLV reverse transcriptase and the Atlas
human cancer cDNA synthesis primer mix, and then puriﬁed with a
NucleoSpin column (Clontech, Palo Alto, CA). The human cancer
membrane array (588 genes, Clontech, Palo Alto, CA) was used for
analysis. The membranes were prehybridized with Expresshyb from
Clontech for 2 h at 68 °C, followed by hybridization with the cDNA
probe overnight at 68 °C. The membranes were then washed four
times in 2× SSC/1% SDS, 30 min each, and two times in 0.1× SSC/0.5%
SDS for 30 min. The membranes were then sealed with plastic wrap
and exposed to a Molecular Dynamics Phosphoimage Screen. Images
were analyzed densitometrically using the AtlasImage software
(Clontech, version 2.01). Gene expression intensities were ﬁrst
corrected with the external background and then globally normalized
as described previously [25].
Real-time RT-PCR analysis
Total RNA was reverse transcribed with MMLV reverse transcrip-
tase and oligodT primers. The PCR primers were designed with Primer
Express software (Applied Biosystems, Foster City, CA, USA) and listed
in Table 1. The Power SYBR Green PCR Master Mix (Applied
Biosystems, Foster City, CA, USA) was used for real-time RT-PCR
analysis. Differences in gene expression between groups were
calculated using cycle time (Ct) values, which were normalized
against β-actin and expressed as relative to control.
Immuncytochemistry
HL-60 cells were collected by centrifugation and ﬁxed with 3%
paraformaldehyde/0.25glutaldehyde in PBS for 10 min, followed by
permeabilization with 0.1% Triton X-100 for 10 min at room
temperature. After washing with PBS, cells were blocked for 60 min
with 1% bovine serum albumin (BSA) in PBS for 30 min, and were
incubated at 37 °C for 1 h with primary antibodies (Santa Cruz
Biotechnology, Santa Cruz, CA) diluted with 1%BSA in PBS (1:100).
After rinsing 3 times in PBS, secondary antibodies [Alexa Fluor 488
conjugated goat anti-mouse IgG (H+L) (Invitrogen) for TIMP1, MYC
and CD14 (1:1000) and Alexa Fluor 543 goat anti-rabbit IgG (H+L)
(Invitrogen) for CASP3 (1:500) diluted in PBS containing 1% BSA]
were added to the cells and incubated at 37 °C for 1 h. PropidiumReverse
TTCCAGCAGATGTG GCATTTGCGGTGGACGAT
GGACACAGACT TTGAAGTTGCCGTCAGAAAACA
TCCAGTCGCTTTG CCCGGGTAAGAATGTGCATAA
CAGGGCTCAAATTT GCACTGGCTGTTTGCTTCAG
GCTAGTGCGATGTTTC GGTCACAGCACATGCCACTT
AACACACAACGTCTT CGCAACAAGTCCTCTTCAGAAA
TTCCTTTGAATCTC AACCACAAGGAAGCCACCAA
ACACTGGACGGGAAT CACGCCGGAGTTCATTGAG
ATGAGACTGGGACCAT CCAGGCCCAGGAGCTTTATT
AGTGGCGTCTAAGC CGTTGACATAGGCCACTTGGA
CAAGAGGCATACCA CCGAAGAGGCCACAACACTT
CCCGCCTGACAGA TCAGAATGTGGGAGCGAATG
TGCCTGCAACGT GTACTTCCCATCCTTGAACAAATACAG
TACTGGAAGTTTGA TCGGCACAGCCAAAGAAGT
AAAGAAGAAACCA CAGCTCTCGGAACATCTCGAA
GGTCCCAGATA GTGGGAACAGGGTGGACACT
CTGTGACTTCATCGT CCATCTGGTACCTGTGGTTCAG
GTGAAGGCTGAGTGT CCTCACCAAGGCCTAACAGATG
CTCTTCTGGCTCAAA CTGAATCCCAGGTTTCGAAGTG
CGGCCAACAA GGCCCAGGTAGTTGCACTTG
CTACATCGACAAGGT ACTTGCCTTGGCCCTTGAG
Table 2
Microarray analysis of JS-K time-response in human HL-60 myeloid leukemia cells at 0.5 μM concentration.
Protein/gene Control at 6 h JS-K 2 h JS-K 4 h JS-K 6 h JS-K 24 h
Apoptosis-related genes
BIRC5, apoptosis inhibitor U75285 2562 (1.0) 0.97 1.05 1.40 1.58⁎
TFAR15, apoptosis-related protein AF022385 560 (1.0) 1.61 1.01 1.99⁎ 2.42⁎
BCL2A1, BCL-2-related protein A1 U29680 4087 (1.0) 0.73 0.95 0.88 2.43⁎
CASP4, caspase-4 precursor U28014 15634 (1.0) 1.12 1.15 1.23 1.42⁎
CFLAR, a FADD- and caspase-related apoptosis inducer Y14040 1579 (1.0) 1.64 1.35 1.42 2.45⁎
DAPK1, death-associated protein kinase 1 X76104 1315 (1.0) 0.91 0.85 0.80 1.73⁎
Acute phase protein genes
EGR1, early growth response protein 1 X52541 2902 (1.0) 0.86 1.41 0.72 1.78⁎
FGR proto-oncogene M19722 12190 (1.0) 0.77 0.94 1.00 2.06⁎
SOD1, cytosolic superoxide dismutase 1 K00065 24504 (1.0) 0.91 0.93 0.80 0.48⁎
LITAF, p53-induced gene 7 AF010312 14070 (1.0) 0.97 0.99 1.03 2.14⁎
TANK, TRAF-interacting protein NF-kappaB activator U59863 2126 (1.0) 0.85 1.25 1.18 1.86⁎
Cell growth related genes
CDK6, cell division protein kinase 6 X66365 42997 (1.0) 0.95 1.10 1.22 1.30⁎
CDK9, cell division protein kinase 9 L25676 6319 (1.0) 0.83 1.07 1.13 1.33⁎
CDKN2D, cyclin-dependent kinase 4 inhibitor; p19-INK4D U40343 5795 (1.0) 0.97 1.44 1.57 3.06⁎
HBEGF, heparin-binding EGF-like growth factor M60278 3400 (1.0) 1.27 1.31 0.93 2.28⁎
IGF1R, insulin-like growth factor I receptor X04434 3241 (1.0) 0.78 0.78 0.86 0.46⁎
IGF1, insulin-like growth factor IA precursor M27544 2561 (1.0) 0.97 1.07 0.35 0.36⁎
MMPs, TIMPs, and others
MMP11, matrix metalloproteinase 11; stromelysin 3 X57766 3880 (1.0) 0.98 1.10 1.53⁎ 2.66⁎
TIMP1, metalloproteinase inhibitor 1 precursor X03124 5093 (1.0) 0.99 1.13 1.40⁎ 2.46⁎
TIMP2, tissue inhibitor of metalloproteinases 2 J05593 856 (1.0) 0.54 0.32 1.33 2.32⁎
CDH5, cadherin 5; VE-cadherin X79981 46856 (1.0) 1.00 1.04 1.14 1.24⁎
VIM, vimentin X56134 6951 (1.0) 1.77 1.66 1.81⁎ 2.16⁎
The base expression levels (control at 6 h) were given in numbers, and were used as (1.0) to compare with time course changes. Data are fold changes over controls from average of
three hybridizations. ⁎Signiﬁcantly different from controls pb0.05.
34 J. Liu et al. / Genomics 94 (2009) 32–38iodide (1 mg/mL) in 1% BSA was used to stain cell nuclei (1:1000) at
room temperature for 10 min. After further washing with PBS, cells
were transferred to Teﬂon imaging chamber for confocal microscopy.
Negative controls were treated similarly except they were not exposed
to primary antibody. Cells were imaged using a Zeiss LSM 510 laser
scanning confocal microscope (Carl Zeiss Inc., Thornwood, NY) with a
Zeiss C-Apochromat 40×/1.2 water objective lens. Data reported areTable 3
Microarray analysis of JS-K concentration-response in human HL-60 myeloid leukemia cells
Protein/gene GenBank access#
Apoptosis related genes
MGMT, 6-O-methylguanine-DNA methyltransferase M29971
Bcl2, apoptosis regulator M14745
Bad, bcl-2 binding component U66879
Bak, bcl2 homologous killer U23765
CASP⁎, caspase-8 precursor U60520
CFLAR, a FADD- and caspase-related apoptosis inducer Y14040
DR5, death receptor 5; cytotoxic TRAIL receptor 2 AF016268
TRAIL, TNF-related apoptosis inducing ligand U57059
TRADD, TNFR1-associated death domain protein L41690
Acute phase protein genes
MAPK8, c-jun N-terminal kinase 1 L26318
Ku (p70/p80) subunit; nuclear factor IV M30938
TANK, TRAF-interacting protein and NF-kappaB activator U59863
Cell growth related genes
CDKN2D, cyclin-dependent kinase 4 inhibitor, p19-INK4D U40343
CCND1, G1/S-speciﬁc cyclin D1 X59798
CCNE, G1/S-speciﬁc cyclin E M73812
GADD45, growth arrest and DNA-damage-inducible protein M60974
VEGFR1, vascular endothelial growth factor receptor 1 X51602
MMPs, TIMPs, and others
MMP11, matrix metalloproteinase 11; stromelysin 3 X57766
TIMP1, metalloproteinase inhibitor 1 precursor X03124
VIM, vimentin X56134
The base expression levels (control at 6 h) were given in numbers, and were used as (1.0) to c
of three hybridizations. ⁎Signiﬁcantly different from controls pb0.05.the results of single experiments that are representative of three
replicate experiments.
Statistical analysis
For microarray analysis, pooled cell samples were performed in
triplicate and the mean and SEM were calculated for statisticalat 6 h time point.
Control at 6 h JS-K 0.25 μM JS-K 0.5 μM JS-K 1.0 μM
2978 (1.0) 0.69 0.75 1.27⁎
4895 (1.0) 1.16 1.12 1.44⁎
1862 (1.0) 2.03⁎ 1.33 1.65⁎
2934 (1.0) 1.03 1.23 1.52⁎
3896 (1.0) 1.73⁎ 1.55⁎ 1.57⁎
1579 (1.0) 1.48 1.42 1.61⁎
2856 (1.0) 1.72⁎ 1.25 1.46⁎
282 (1.0) 1.61 1.06 2.66⁎
793 (1.0) 1.27 1.19 2.05⁎
2520 (1.0) 0.95 1.18 1.51⁎
3380 (1.0) 1.53 1.33 1.38⁎
2126 (1.0) 0.82 1.18 1.64⁎
5795 (1.0) 1.61 1.57 1.41⁎
1255 (1.0) 0.63 0.38⁎ 0.33⁎
2318 (1.0) 0.52 0.16⁎ 0.15⁎
4696 (1.0) 1.06 0.97 1.26⁎
17352 (1.0) 1.47 1.36⁎ 1.44⁎
3880 (1.0) 1.26 1.53 1.44⁎
5093 (1.0) 1.11 1.40⁎ 1.42⁎
6951 (1.0) 1.52 1.81⁎ 1.67⁎
omparewith dose-dependent changes. Data are fold changes over controls from average
Fig. 2. Effect of JS-K on the expression of cell differentiation-related genes. HL-60 cells
were treated with 0, 0.25, 0.5, and 1.0 μM JS-K for 24 h, and total puriﬁed RNA was
subjected to real-time RT-PCR analysis. Data are mean and SEM (n=3). ⁎Signiﬁcantly
different from controls, pb0.05.
35J. Liu et al. / Genomics 94 (2009) 32–38analysis [25]; for RT-PCR analysis, individual samples (n=3) were
used. For comparisons of gene expression between two groups, the
Students' t test was used. For comparisons among 3 or more groups,
data were analyzed using a one-way analysis of variance, followed by
Duncan's multiple range tests. The level of signiﬁcance was set at
pb0.05 in all cases.
Results
JS-K alters gene expression in HL-60 cells in a concentration- and
time-dependent manner
In order to determine gene expression changes, cDNA microarrays
were performed following treatment of HL-60 cells with 0.5 μM JS-K
for 2, 4, 6, and 24 h (time-course) and at 6 h after treatment with 0,
0.25, 0.5, and 1.0 μM JS-K (dose–response) in triplicates. The
expression of approximately 10% or the 600 genes on the human
cancer array was signiﬁcantly altered. Among these signiﬁcantly
altered genes, 20 were selected from the time–course (Table 2) and
dose–response (Table 3) studies. Altered genes included genes related
to apoptosis, acute phase protein genes, cell growth regulators, matrix
metalloproteases (MMPs), tissue inhibitors of metalloproteases
(TIMPs) and others. In general, JS-K-induced gene expression changes
occurred in a time- and concentration-dependent manner. The
highest changes in gene expression occurred after 24 h treatments;
while at the 6 h time-point, the highest concentration (1.0 μM)
produced the most signiﬁcant changes. Thus, HL-60 cells treated with
various concentrations of JS-K (0, 0.25, 0.5, and 1.0 μM) for 24 h were
further analyzed with RT-PCR for the expression of selected genes
based on the potential biological signiﬁcance.
JS-K induced apoptotic gene expression correspondence to apoptosis in
HL-60 cells
JS-K treatment of HL-60 cells induces apoptosis [7, 13]. Consistent
with JS-K-induced apoptosis in HL-60 cells (data not shown), the
expression of caspase (CASP3) (apoptosis executor) and CASP8
(apoptosis initiator) were increased about 3 fold in JS-K-treated cells
(Fig. 1). In addition to Casp activation, the apoptosis protein gene
Casper (data not shown) was also increased 3 fold. Expressions of
TNF and IL1B were increased 2.5 and 9 folds, respectively (Fig. 1), in
agreement with previous observations of the effects of NO on HL-60Fig. 1. Effect of JS-K on the expression of apoptosis-related genes. HL-60 cells were
treated with 0, 0.25, 0.5, and 1.0 μM JS-K for 24 h, and total puriﬁed RNA was subjected
to real-time RT-PCR analysis. Data are mean and SEM (n=3). ⁎Signiﬁcantly different
from controls, pb0.05.cells [1]. RT-PCR conﬁrmed and extended microarray results. One can
therefore conclude that gene expression analysis clearly indicates that
apoptotic pathways were activated by JS-K in HL-60 cells.
JS-K induced the differentiation genes in HL-60 cells
An important effect of NO on leukemia cells (including NO
generated by JS-K) is the induction of differentiation along the
monocytic pathway [1,2,7]. Thus, the effects of JS-K on monocytic
differentiation markers were examined. As shown in Fig. 2, JS-K
treatment increased the expression of ITGAM and CD14. The increase
in CD14 was as high as 19-fold at the highest dose of JS-K. Expression
of vimentin (VIM), a gene associated with the late differentiation of
HL-60 cells [15], was also increased by 4.5 folds (Fig. 2).
JS-K altered the expression of acute phase response genes in HL-60 cells
JS-K is known to activate acute phase proteins such as c-jun and c-fos
and MAP kinases in Hep3B hepatoma cells, CAsE cells, and multiple
myeloma cells [8–10]. In microarray analysis, acute phase protein genes
EGR1, FGR, MAP kinases (MAPK8), and p53-induced protein LITAF were
all increased;while cell growth related genes suchas cyclins and insulin-
like growth factors (IGFs)weredecreased (Tables 2 and3). Real-timeRT-
PCR (Fig. 3) shows that JS-K increased the expression of TP53, JUN, and
EGR1 in a dose-dependent fashion, but decreased the expression of
MYC and CCNE1. In HL-60 cells, the expression ofMYC had been shown
to be depressed by the NO donor sodium nitroprusside and NO gas [1],
and the downregulation of c-myc by valproic acid was associated with
HL-60 cell growth arrest [16].
JS-K increased the expression of genes of anti-angiogenesis and
anti-tumor cell migration
JS-K has been shown to inhibit angiogenesis in vitro [17]. Thus, we
examined the effect of JS-K on anti-angiogenesis gene expression in
HL-60 cells. Expression of the anti-angiogenesis gene thrombospodin-
1 (THBS1) and its receptor CD36 were signiﬁcantly increased by JS-K
in a concentration-dependent manner (Fig. 4). One of the interesting
ﬁndings from the microarray analysis was alterations in expression of
matrix metalloproteinases (MMPs) and tissue inhibitor of matrix
metalloproteinases (TIMPs) (Tables 2 and 3). To conﬁrm microarray
Fig. 5. Effect of JS-K on the expression of MMPs and TIMPs. HL-60 cells were treated
with 0, 0.25, 0.5, and 1.0 μM JS-K for 24 h, and total puriﬁed RNA was subjected to real-
time RT-PCR analysis. Data are mean and SEM (n=3). ⁎Signiﬁcantly different from
controls, pb0.05.
Fig. 3. Effect of JS-K on the expression of acute phase protein genes. HL-60 cells were
treated with 0, 0.25, 0.5, and 1.0 μM JS-K for 24 h, and total puriﬁed RNA was subjected
to real-time RT-PCR analysis. Data are mean and SEM (n=3). ⁎Signiﬁcantly different
from controls, pb0.05.
36 J. Liu et al. / Genomics 94 (2009) 32–38ﬁndings, the expression of MMP11, TIMP1, TIMP2, and TIMP 3 were
examined (Fig. 5). Consistent with microarray ﬁndings, these genes
were all upregulated over 3 folds, and up to 6-fold increase in TIMP1
expression was evident. Of note is that TIMP1 plays an antiangiogen-
esis role in mammalian cells and the inhibition of TIMP1 enhances
angiogenesis both in vivo and in vitro [18].
Confocal imaging analysis of JS-K altered protein expression
in HL-60 cells
To verify the above gene expression changes, confocal imaging
analysis was conducted to examine the expression and localization of
relevant proteins at the cellular levels (Fig. 6). The intensity of
apoptosis executor CASP3 was markedly enhanced, especially in
apoptotic cells; the expression of CD14 was also markedly enhanced,
mainly in the cytoplasma; while the expression of MYC wasFig. 4. Effect of JS-K on the expression of anti-angiogenesis-related genes. HL-60 cells
were treated with 0, 0.25, 0.5, and 1.0 μM JS-K for 24 h, and total puriﬁed RNA was
subjected to real-time RT-PCR analysis. Data are mean and SEM (n=3). ⁎Signiﬁcantly
different from controls, pb0.05.
Fig. 6. Representative confocal image analysis of the expression of caspase-3, CD14,
c-myc, and TIMP1. HL-60 cells were treated with 1.0 μM JS-K or left untreated for 24 h.
Cells were then harvested, ﬁxed, permeabilized, and incubated with speciﬁc primary
antibodies and ﬂuorescence labeled secondary antibodies for confocal imaging as
detailed in Materials and methods.
37J. Liu et al. / Genomics 94 (2009) 32–38attenuated, consistent with mRNA data; and the expression of TIMP1
was universally increased, mainly located in the cytosol of HL-60 cells.
Discussion
This study initially used cDNA microarray to proﬁle gene expres-
sion changes produced by JS-K in human leukemia HL-60 cells. Both
time–course and dose–response studies showed that JS-K modulated
the expression of genes related to apoptosis, cell differentiation, acute
phase response, anti-angiogenesis, and tumor cell migration. Real-
time RT-PCR and confocal image analysis at the 24 h time point
veriﬁed the selected key gene expression changes at both transcript
levels and the protein levels. Thus, multiple molecular targets are
clearly involved in anticancer effects of JS-K.
NO and NO donors have long been recognized to induce human
leukemia cell apoptosis and differentiation [1,2,7]. The apoptotic
effects of NO prodrugs are also associated with acute phase protein/
gene induction (e.g., JUN and FOS) andMAP kinase pathway activation
(e.g., JNK and ERK) [8–10,19]. The TNF, TP53, and Fas/CD95 pathways,
as well as activation of caspase cascades and apoptotic proteins (such
as Bad, BAX, and MCL1), are involved in JS-K-induced apoptosis in
various tumor cells [7,10,13]. The current gene expression analysis
clearly demonstrated that JS-K induced apoptosis and apoptosis-
related gene expression are a major mechanism for tumor cell killing.
Induction of human myeloid cell differentiation is an important
anti-leukemic mechanism for NO donors, including JS-K [1,2,7]. In the
present study, the expression of CD14, a marker of monocytic
differentiation, was increased up to 19 fold by JS-K, an effect too
dramatic to ignore. Expression of CD11b and vimentin was also
increased about 4 fold. Both molecules are known to be involved in
NO-induced differentiation in HL-60 cells [1,2,15]. The induction of
leukemia cell differentiation is an important mechanism for JS-K's
anti-leukemic properties.
JS-K is known to activate acute phase proteins such as c-jun and c-
fos andMAP kinases in Hep3B hepatoma cells, CAsE cells, andmultiple
myeloma cells [8–10]. In microarray analysis, a number of acute phase
protein genes were increased, including p53 and early growth
response protein-1 (EGR1). A recent work demonstrates that JS-K
inhibition of ubiquitin-activating enzyme E1 activity may preferen-
tially induce apoptosis in p53-expressing tumor cells [20]. In contrast
to upregulation of other acute proteins, the expression of MYC,
another major acute phase protein, was decreased by JS-K at both
transcript and protein levels, together with decreased expression of
CCNE1. These effects may be speciﬁc for myeloid leukemia cells, as it
has been reported that the expression of MYC was decreased by the
NO donor sodium nitroprusside and NO gas [1], and the down-
regulation of MYC is associated with HL-60 cell growth arrest [16].
JS-K has been shown to block angiogenesis by inhibiting
proliferation, migration, and cord formation in human umbilical
vein endothelial cell cultures [17]. This prompted us to examine the
expression of anti-angiogenesis genes, and indeed, two of anti-
angiogenesis protein genes, TSP-1 and its receptor CD36, were
signiﬁcantly increased by JS-K, supporting a role for JS-K as an anti-
angiogenesis modulator. NO has been shown to have a dual, biphasic
response in tumor biology, including the modulation of the gate-
keeper THBS1 in tumor angiogenesis [21,22]. TSP-1 is known to act
through its receptor CD36 to inhibit cell proliferation and tumor cell
angiogenesis [22]. Activation of THBS1 and CD36 is also an important
pathway to initiate tumor cell apoptosis viaMAP kinases and to induce
p53-mediated cascade with resultant cell growth arrest [23]. It should
also be noted that increased expression of TIMP1 in the present study
can also exert an anti-angiogenic effect [18,24].
Microarray analysis revealed that JS-K increased the expression of
MMPs and TIMPs, which was further veriﬁed by real-time RT-PCR
analysis. In breast cancer cells, induction of TIMP2 and TIMP1 by JS-K
is thought to play an important role in JS-K's anti-invasive effectsagainst breast cancer MDA-MB-231, F10, and MCF-7/COX2 cells [25].
MMPs and TIMPS regulate extracellular matrix turnover and remodel-
ing during normal development and pathogenesis. They also play
important roles in tumor cell signaling, tumor cell progression,
angiogenesis, and tumor metastasis [24–26]. The dramatic induction
of TIMPs by JS-K in HL-60 myeloid leukemia cells is a novel ﬁnding,
and its contribution to inhibit tumor cell migration and metastasis is
worthy of further investigation.
The exact mechanism by which JS-K effects these gene expression
changes in acute myeloid leukemia cells are unknown. As a NO
generator, JS-K is bound to cause signiﬁcant oxidative stress with
resultant changes in stress response genes. Kiziltepe et al. have also
observed that JS-K induces DNA strand breaks in multiple myeloma
cells [10]. A similar mechanism is likely at play in myeloid leukemia
cells with resultant induction of stress response genes. However, NO
delivery to malignant cells is not the only cytotoxic mechanism for JS-
K. Arylation of free protein thiols with resultant modiﬁcation of
protein function is also likely to play a role in JS-K's anti-neoplastic
effects [11]. Furthermore, Townsend et al. have shown that the JS-K
derivative PABA/NO is cytotoxic to ovarian cancer cells through a
mechanism involving protein thiol glutathionylation [27]. It is there-
fore likely that JS-K modulates gene expression through modiﬁcation
of key transcription factors or signaling molecules via arylation and
glutathionylation reactions.
In summary, this gene expression analysis revealed several
potential mechanisms by which JS-K kills HL-60 cells in a concentra-
tion- and time-dependent manner. These mechanisms include
activation of the p53- and TNF-α-mediated apoptotic pathways via
acute phase responses, activation of the caspase cascade and
induction of differentiation in myelogenous leukemia cells. In
addition, JS-K induction of anti-angiogenesis gene expression and
increased expression of TIMPs suggest a potential effect against tumor
cell invasion and metastasis. These results could shed light on
molecular targets for anticancer effects of JS-K, a lead O2-arylated
diazeniumdiolate NO prodrug.
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